| Issuer | % of Class | Filed |
|---|---|---|
|
Cabaletta Bio, Inc.
13G/A
Amendment 3
CABA · 12674W109
|
9.6% |
11/16/2026
Event 9/30/2026
|
|
Cabaletta Bio, Inc.
13G/A
Amendment 2
CABA · 12674W109
|
10.0% |
8/14/2026
Event 6/30/2026
|
|
Kyverna Therapeutics, Inc.
13G/A
Amendment 2
KYTX · 501976104
|
4.8% |
8/14/2026
Event 6/30/2026
|
|
Kyverna Therapeutics, Inc.
13G/A
Amendment 1
KYTX · 501976104
|
5.4% |
2/17/2026
Event 12/31/2025
|
|
Century Therapeutics, Inc.
13G/A
Amendment 1
IPSC · 15673T100
|
4.1% |
11/14/2025
Event 9/30/2025
|
|
Cabaletta Bio, Inc.
13G/A
Amendment 1
CABA · 12674W109
|
10.0% |
8/14/2025
Event 6/30/2025
|
|
Disc Medicine, Inc.
13G/A
Amendment 3
IRON · 254604101
|
3.3% |
2/14/2025
Event 12/31/2024
|
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.